Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline

Abstract

The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma. M ETHODOLOGYThis Guideline was compiled according to the BSH process at https:// b-s-h. org. uk/ media/ 16732/ bsh-guida nce-devel opmen t-proce ss-dec-5-18. pdf and represents best practice in both teaching and district hospitals in the United Kingdom. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http:// www. grade worki nggro up. org. Literature review detailsRecommendations included a systematic review of published English language literature from publication of previous British Society for Haematology (BSH) Management of Mantle Cell lymphoma Guidelines 2018 up to 02/2023. The search was limited to English language publications and conference abstracts. Titles/abstracts obtained were curated and manually reviewed by the writing group who conducted additional searches, using sub-section heading terms. In addition, there are some further pertinent references and a consensus of expert opinion where no published data are available. PubMed, MEDLINE, Embase, Cochrane databases and Web of Science were searched using the preliminary search terms: MCL OR Mantle Cell lymphoma OR aggressive Mantle Cell lymphoma OR indolent Mantle Cell lymphoma. Systematic reviews, meta-analysis including guidelines from other countries, prospective clinical trials,

Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report

“…The prognosis of MCL is related to numerous factors, such as stage, risk factors, gene mutations and chromosome translocations ( 7 ). The International Prognostic Index of MCL (MIPI) includes age, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and white blood cell (WBC) count at initial diagnosis ( 8 , 9 ). According to the MIPI, risk groups describing the prognosis of patients with MCL are divided into low-, intermediate- and high-risk groups ( 8 , 9 ).…”

“…The International Prognostic Index of MCL (MIPI) includes age, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and white blood cell (WBC) count at initial diagnosis ( 8 , 9 ). According to the MIPI, risk groups describing the prognosis of patients with MCL are divided into low-, intermediate- and high-risk groups ( 8 , 9 ). The present case involved a 56-year-old male patient with mild limitations in physical activity.…”

“…The present case involved a 56-year-old male patient with mild limitations in physical activity. The initial diagnosis revealed normal levels of LDH and WBC counts, indicating that the patient was in the low-risk group ( 9 ). In FISH, no abnormalities were detected in the IGH and CCND1 genes, which may indicate that these two genes did not undergo the expected mutations in this specific case.…”

Letting the mantle out of the bag

“…In their paper, Eyre et al, 1 report excellent guidelines on the diagnosis and treatment of mantle cell lymphoma (MCL). MCL is an aggressive histotype of non‐Hodgkin lymphoma (NHL), that was recognized by histopathologists in the mid‐70s, but came of age in the mid‐90s, when pathological and immunological features, and the cytogenetic abnormality t(11;14)(q13;q32) were described 2 .…”